Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Myasthenia Gravis 1

Interventions

Specimen Handling 648pembrolizumab 606Magnetic Resonance Spectroscopy 559Carboplatin 446Cyclophosphamide 394Cisplatin 394Biopsy 376Nivolumab 325Paclitaxel 324Gemcitabine 317Radiotherapy 295Bevacizumab 245Dexamethasone 224fludarabine 214Docetaxel 202durvalumab 194Oxaliplatin 191venetoclax 187atezolizumab 179Fluorouracil 179Rituximab 174Capecitabine 170Pemetrexed 169Radiation 164Doxorubicin 164Radiosurgery 161Ipilimumab 148Lenalidomide 143Leucovorin 139Etoposide 139

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HBM9161 × 90 days × Clear all
NCT05332210 2026-04-28

Evaluate the Safety of HBM9161 (HL161) Subcutaneous Injection in Patients With Generalized Myasthenia Gravis

Harbour BioMed (Guangzhou) Co. Ltd.

Phase 3 Completed
111 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡